• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Reva inks distro deal for bioresorbable scaffolds in Turkey

April 3, 2018 By Sarah Faulkner

Reva MedicalReva Medical (ASX:RVA) inked a distribution deal with Kardionet Healthcare & Foreign Trading to launch commercial operations in Turkey for its bioresorbable scaffold tech, the company reported today.

According to the terms of the deal, Kardionet will be responsible for sales, marketing, customer training and support for Reva’s Fantom and Fantom Encore bioresorbable devices in Turkey. The San Diego, Calif.-based company expects to start selling the scaffolds in the second quarter of 2018.

“We are very excited to bring the Fantom bioresorbable scaffold to patients in Turkey. We believe that it will be well received by physicians, who have experience with first generation bioresorbable scaffolds and have expressed interest in Fantom’s x-ray visibility, thinner strut profile, and improved ease-of-use,” Carmelo Mastrandrea, Reva’s VP of Europe, said in prepared remarks. “Kardionet’s proven success with interventional cardiology devices and their demonstrated support of patients and physicians make them an ideal distributor for us in Turkey.”

“Reva’s top corporate priority is ensuring Fantom’s commercial success. We began our first phase of launch with our direct sales force in Germany, Switzerland, and Austria last year. The distribution agreement with Kardionet marks the start of our second phase of launch for Fantom,” CEO Reggie Groves added.

Last month, Reva touted that its Fantom Encore device was used for the first time in Switzerland. The sirolimus-eluting device, which is made from Reva’s proprietary Tyrocore polymer, features a 95-micron strut profile and x-ray visibility.

The company launched its commercial operations in Switzerland last year and has since won CE Mark approval in the European Union for its Fantom Encore device.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Distribution, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular, Wall Street Beat Tagged With: Reva Medical

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS